TL;DR
An important role for BIM is suggested in eliminating activated T cells even when IL-2 is abundant, working in conjunction with Fas to eliminate chronically stimulated T cells and maintain immune homeostasis.
Cancer progression following an initial response to immunotherapy (secondary resistance; 2°R) is a major and poorly understood problem. We treated mice bearing B16 melanoma with a combination of a regulatory T cell (Treg) depleting, non-IL-2 blocking antibody (anti-CD25NIB) and an autologous cancer cell vaccine (GVAX)....
Chronic or persistent T cell activation is widely thought to culminate in T cell exhaustion, yet how autoreactive CD8⁺ T cells remain functionally intact despite sustained self-antigen exposure is poorly understood. In chronic infection and cancer this durability is attributed to stem-like, TCF1⁺ PD-1⁺ progenitor-exhau...
T cells (Tregs) maintain immune tolerance, yet how they selectively eliminate cognate CD4+ effector T cells remains unclear. We propose a co-activation-dependent elimination mechanism, conceptually akin to synthetic lethality. Using in vitro co-cultures, we show that simultaneous peptide-MHC II recognition by Tregs and...
Combined TNF and JAK inhibition as an effective therapeutic strategy for TBK1 deficiency is supported and cytotoxic lymphocytes are the primary drivers of aberrant cell death through a T cell-myeloid axis dependent on TNF/IFN-γ synergism.
A novel and uniformly applicable TCR:ICOS format that supports fitter T cell products for adoptive cell therapy and identifies a single amino acid change in the cytosolic tail which enabled functional surface expression without proneness to TCR mispairing nor competition for CD3.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
